1 Min Read
April 11 (Reuters) - AzurRx Biopharma Inc
* AzurRx provides update on MS1819 phase II trial
* AzurRx Biopharma Inc - Early results indicate that MS1819 exhibits a favorable safety profile Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.